The European Commission has cleared Takeda’s acquisition of Shire, the company announced in a press release.
The clearance is conditional upon the companies divesting of Shire’s SHP647 and associated rights in order to avoid overlap in inflammatory bowel disease products, the release said.
“We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,” Takeda President and CEO Christophe Weber said in the release.
The acquisition was previously cleared by the U.S. Federal Trade
Uncategorized